FIELD: biotechnology.
SUBSTANCE: methods of treating a disorder responsive to treatment with serotype E botulinum neurotoxin (BoNT/E), as well as cosmetic methods of suppressing wrinkles in the upper face, where the methods include administering BoNT/E to a human subject at a dose of 0.04 to 4 ng, where BoNT/E is a recombinant BoNT/E that does not contain complexing proteins are presented.
EFFECT: inventions allow to achieve maximum inhibition of neurotransmitter secretion from target cell or target tissue within ≤13 days after BoNT/E administration and reduce inhibition of neurotransmitter secretion from target cell or target tissue to >25% on day 14 after BoNT/E administration, leading to an effective treatment of the disorder responsive to serotype E botulinum neurotoxin.
31 cl, 14 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
| HYBRID NEUROTOXINS | 2017 |
|
RU2782382C2 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2729118C2 |
| BOTULINUM NEUROTOXIN BIOHYBRID | 2019 |
|
RU2816855C2 |
| COMPLEX, AGENT AND APPLICATION OF TYPE A BOTULINUM TOXIN CLOSTRIDIUM BOTULINUM | 2020 |
|
RU2783511C1 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2019 |
|
RU2727402C1 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
